Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

PD-1 inhibition alone or combined with CTLA-4 blockade in MSI-H/dMMR metastatic colorectal cancer: refining treatment intensity

Clinical studies indicate that nivolumab plus ipilimumab is associated with higher objective response rates and longer progression-free survival compared to PD-1 monotherapy, and randomized data from the Checkmate 8HW trial suggest a clinically meaningful trend toward improved overall survival with combination therapy.

L. Esposito, B. Ceredi, C. Gallio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.